An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions

(2014) Ursula Amstutz et al.   EPILEPSIA

Recurrence and Mortality Following Severe Cutaneous Adverse Reactions

(2014) Yaron Finkelstein et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response

(2013) J. Yun et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine

(2013) YongLi Guo et al.   Science China-Life Sciences

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol

(2012) Lisa K. Stamp et al.   ARTHRITIS AND RHEUMATISM

HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency

(2011) J.-W. Jung et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan

(2011) Pei Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans

(2011) Hye-Ryun Kang et al.   Pharmacogenetics and Genomics

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

(2009) Wichittra Tassaneeyakul et al.   Pharmacogenetics and Genomics

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study

(2007) Maja Mockenhaupt et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY